BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9829727)

  • 21. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells.
    Bostedt KT; Schmid C; Ghirlanda-Keller C; Olie R; Winterhalter KH; Zapf J
    Exp Cell Res; 2001 Dec; 271(2):368-77. PubMed ID: 11716549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
    Alexia C; Fallot G; Lasfer M; Schweizer-Groyer G; Groyer A
    Biochem Pharmacol; 2004 Sep; 68(6):1003-15. PubMed ID: 15313394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice.
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Xu XH
    Cell Biol Int; 2007 May; 31(5):500-7. PubMed ID: 17196841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
    Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
    Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines.
    Friend KE; Khandwala HM; Flyvbjerg A; Hill H; Li J; McCutcheon IE
    Growth Horm IGF Res; 2001 Apr; 11(2):84-91. PubMed ID: 11472074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation.
    Mikheev AM; Mikheeva SA; Liu B; Cohen P; Zarbl H
    Carcinogenesis; 2004 Jan; 25(1):47-59. PubMed ID: 14555616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
    Carboni JM; Lee AV; Hadsell DL; Rowley BR; Lee FY; Bol DK; Camuso AE; Gottardis M; Greer AF; Ho CP; Hurlburt W; Li A; Saulnier M; Velaparthi U; Wang C; Wen ML; Westhouse RA; Wittman M; Zimmermann K; Rupnow BA; Wong TW
    Cancer Res; 2005 May; 65(9):3781-7. PubMed ID: 15867374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation.
    Li M; He Z; Ermakova S; Zheng D; Tang F; Cho YY; Zhu F; Ma WY; Sham Y; Rogozin EA; Bode AM; Cao Y; Dong Z
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):598-605. PubMed ID: 17372258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumor growth.
    Li W; Hyun T; Heller M; Yam A; Flechner L; Pierce JH; Rudikoff S
    Cancer Res; 2000 Jul; 60(14):3909-15. PubMed ID: 10919668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR.
    Wu J; Haugk K; Plymate SR
    Horm Metab Res; 2003; 35(11-12):751-7. PubMed ID: 14710354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone.
    McTavish H; Griffin RJ; Terai K; Dudek AZ
    Transl Res; 2009 Jun; 153(6):275-82. PubMed ID: 19446281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor family in malignant haemangiopericytomas: the expression and role of insulin-like growth factor I receptor.
    Pavelić K; Pavelić ZP; Cabrijan T; Karner I; Samarzija M; Stambrook PJ
    J Pathol; 1999 May; 188(1):69-75. PubMed ID: 10398143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.
    Vitale G; van Koetsveld PM; de Herder WW; van der Wansem K; Janssen JA; Colao A; Lombardi G; Lamberts SW; Hofland LJ
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E559-66. PubMed ID: 19141687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of anchorage-independent cell growth, adhesion, and cyclin D1 gene expression by a dominant negative mutant of a tyrosine phosphatase.
    Mitra SK; Swarup G
    Exp Cell Res; 2001 Oct; 270(1):32-44. PubMed ID: 11597125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.